Becker's Healthcare July 24, 2024
On July 17, Roche published early results from a phase 1 trial of an experimental GLP-1 pill for obesity. That day, the drugmaker gained $16.8 billion in its market value, Bloomberg reported.
The GLP-1 drug class, which includes blockbuster medicines for diabetes and weight loss, is expected to boost the U.S. economy by $1 trillion within the next four years or so, according to Goldman Sachs analysts.
Pharmaceutical companies have been reaping the benefits in the form of soaring shares based on small trials, according to Bloomberg.
Roche’s phase 1 trial enrolled 25 adults who are obese and do not have Type 2 diabetes. Within four weeks, the daily pill led...
Today's Sponsors
Today's Sponsor